. . "Coducept"@en . . . . . . "O(3)-Methylmorphine"@en . . . . . . . . . . . . . . . . . "L-Codeine"@en . . . . . . . . . . . . . . . . . . . . . "Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours."@en . . . . . . . . . . . . . . . . . . . . . . "Take with food, food reduces irritation."@en . . . . . . . . . . . "Codeinum"@en . . . . . "Apparent volume of distribution = 3-6 L/kg "@en . . . . . . . . . . . . . . . . . . "Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Codeine's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability."@en . . . . . . "Codeine anhydrous"@en . . . . "Codicept"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. [PubChem]"@en . . . . . . . . . . . "Methylmorphine"@en . . . "Respiratory depression, sedation and miosis and common symptoms of overdose. Other symptoms include nausea, vomiting, skeletal muscle flaccidity, bradycardia, hypotension, and cool, clammy skin. Apnea and death may ensue."@en . . . . . . . . "Morphine monomethyl ether"@en . . . "Codeine"@en . "For treatment and management of pain (systemic). It is also used as an antidiarrheal and as a cough suppressant."@en . . "(5\u03B1,6\u03B1)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol"@en . "Humans and other mammals"@en . "morphine monomethyl ether"@en . . . . "To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables)."@en . "90% of the total dose of codeine is excreted through the kidneys, of which 10% is unchanged codeine. "@en . "7,8-Didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol"@en . "# Schroeder K, Fahey T: Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001831. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15495019 # Vree TB, van Dongen RT, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000 Jul-Aug;54(6):395-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11092114 # Srinivasan V, Wielbo D, Tebbett IR: Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain. 1997;1(3):185-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15102399"@en . "3-methylmorphine"@en . "Codein"@en . "morphine 3-methyl ether"@en . . "3-Methylmorphin"@en . . "Cod\u00E9ine"@en . "Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, \"Process for the preparation of codeine from morphine.\" U.S. Patent US4764615, issued May, 1912."@en . "Code\u00EDna"@en . "Well absorbed following oral administration with a bioavailability of approximately 90%. Maximum plasma concentration occurs 60 minutes post-administration. Food does not effect the rate or extent of absorption of codeine. "@en . "illicit"@en . "76-57-3"@en . . "(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol"@en . . "morphine-3-methyl ether"@en . . " "@en . . " "@en . . . "approved"@en . . "Avoid alcohol."@en . . . "7-25% bound to plasma proteins. "@en . . . . .